Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Medicines
Special Issues
New Innovations in Biomedical Engineering
share announcement

New Innovations in Biomedical Engineering

A special issue of Medicines (ISSN 2305-6320).

Deadline for manuscript submissions: closed (30 April 2018) | Viewed by 21741

Special Issue Editor

Prof. Dr. Gerhard Litscher

E-Mail Website
Guest Editor
High-Tech Acupuncture and Digital Chinese Medicine, Swiss University of Traditional Chinese Medicine, 5330 Bad Zurzach, Switzerland
Interests: photobiomodulation; laser therapy; laser acupuncture; laser medicine; evidence-based complementary medicine
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Biomedical Engineering is the application of engineering principles and design concepts to medicine and biology for healthcare purposes. Biomedical Engineering researchers bring their skills to a broad range of fields ranging from Clinical Engineers managing all aspects of the health technology lifecycle; to Engineers in industry developing and manufacturing medical devices; and Rehabilitation Engineers taking lead roles as front-line clinicians in the assessment, design, and manufacture of assistive technology for people with disabilities.

This Special Issue is open to manuscripts on all types of biomedical engineering. Theoretical, animal experimental studies, investigations in healthy volunteers, short reports, letters to editors, study designs and clinical studies, and case reports and photo essays are welcome.

We look forward to your valuable manuscript. Together with the managing editorial team from Medicines, we will do our best to support you by publishing your important data.

Prof. DDr. Gerhard Litscher
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicines is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

Jump to: Other

11 pages, 531 KiB  
Review
How Nanotechnology and Biomedical Engineering Are Supporting the Identification of Predictive Biomarkers in Neuro-Oncology
by Mario Ganau, Marco Paris, Nikolaos Syrmos, Laura Ganau, Gianfranco K.I. Ligarotti, Ali Moghaddamjou, Lara Prisco, Rossano Ambu and Salvatore Chibbaro
Medicines 2018, 5(1), 23; https://doi.org/10.3390/medicines5010023 - 26 Feb 2018
Cited by 18 | Viewed by 4754
Abstract
The field of neuro-oncology is rapidly progressing and internalizing many of the recent discoveries coming from research conducted in basic science laboratories worldwide. This systematic review aims to summarize the impact of nanotechnology and biomedical engineering in defining clinically meaningful predictive biomarkers with [...] Read more.
The field of neuro-oncology is rapidly progressing and internalizing many of the recent discoveries coming from research conducted in basic science laboratories worldwide. This systematic review aims to summarize the impact of nanotechnology and biomedical engineering in defining clinically meaningful predictive biomarkers with a potential application in the management of patients with brain tumors. Data were collected through a review of the existing English literature performed on Scopus, MEDLINE, MEDLINE in Process, EMBASE, and/or Cochrane Central Register of Controlled Trials: all available basic science and clinical papers relevant to address the above-stated research question were included and analyzed in this study. Based on the results of this systematic review we can conclude that: (1) the advances in nanotechnology and bioengineering are supporting tremendous efforts in optimizing the methods for genomic, epigenomic and proteomic profiling; (2) a successful translational approach is attempting to identify a growing number of biomarkers, some of which appear to be promising candidates in many areas of neuro-oncology; (3) the designing of Randomized Controlled Trials will be warranted to better define the prognostic value of those biomarkers and biosignatures. Full article
(This article belongs to the Special Issue New Innovations in Biomedical Engineering)
►▼ Show Figures

Graphical abstract

11 pages, 693 KiB  
Review
Current and Future Applications of Biomedical Engineering for Proteomic Profiling: Predictive Biomarkers in Neuro-Traumatology
by Mario Ganau, Nikolaos Syrmos, Marco Paris, Laura Ganau, Gianfranco K.I. Ligarotti, Ali Moghaddamjou, Salvatore Chibbaro, Andrea Soddu, Rossano Ambu and Lara Prisco
Medicines 2018, 5(1), 19; https://doi.org/10.3390/medicines5010019 - 5 Feb 2018
Cited by 18 | Viewed by 4678
Abstract
This systematic review aims to summarize the impact of nanotechnology and biomedical engineering in defining clinically meaningful predictive biomarkers in patients with traumatic brain injury (TBI), a critical worldwide health problem with an estimated 10 billion people affected annually worldwide. Data were collected [...] Read more.
This systematic review aims to summarize the impact of nanotechnology and biomedical engineering in defining clinically meaningful predictive biomarkers in patients with traumatic brain injury (TBI), a critical worldwide health problem with an estimated 10 billion people affected annually worldwide. Data were collected through a review of the existing English literature performed on Scopus, MEDLINE, MEDLINE in Process, EMBASE, and/or Cochrane Central Register of Controlled Trials. Only experimental articles revolving around the management of TBI, in which the role of new devices based on innovative discoveries coming from the field of nanotechnology and biomedical engineering were highlighted, have been included and analyzed in this study. Based on theresults gathered from this research on innovative methods for genomics, epigenomics, and proteomics, their future application in this field seems promising. Despite the outstanding technical challenges of identifying reliable biosignatures for TBI and the mixed nature of studies herein described (single cells proteomics, biofilms, sensors, etc.), the clinical implementation of those discoveries will allow us to gain confidence in the use of advanced neuromonitoring modalities with a potential dramatic improvement in the management of those patients. Full article
(This article belongs to the Special Issue New Innovations in Biomedical Engineering)
►▼ Show Figures

Graphical abstract

Other

Jump to: Review

9 pages, 1072 KiB  
Perspective
Understanding the Pathological Basis of Neurological Diseases Through Diagnostic Platforms Based on Innovations in Biomedical Engineering: New Concepts and Theranostics Perspectives
by Laura Ganau, Lara Prisco, Gianfranco K.I. Ligarotti, Rossano Ambu and Mario Ganau
Medicines 2018, 5(1), 22; https://doi.org/10.3390/medicines5010022 - 25 Feb 2018
Cited by 32 | Viewed by 4217
Abstract
The pace of advancement of genomics and proteomics together with the recent understanding of the molecular basis behind rare diseases could lead in the near future to significant advances in the diagnosing and treating of many pathological conditions. Innovative diagnostic platforms based on [...] Read more.
The pace of advancement of genomics and proteomics together with the recent understanding of the molecular basis behind rare diseases could lead in the near future to significant advances in the diagnosing and treating of many pathological conditions. Innovative diagnostic platforms based on biomedical engineering (microdialysis and proteomics, biochip analysis, non-invasive impedance spectroscopy, etc.) are introduced at a rapid speed in clinical practice: this article primarily aims to highlight how such platforms will advance our understanding of the pathological basis of neurological diseases. An overview of the clinical challenges and regulatory hurdles facing the introduction of such platforms in clinical practice, as well as their potential impact on patient management, will complement the discussion on foreseeable theranostic perspectives. Indeed, the techniques outlined in this article are revolutionizing how we (1) identify biomarkers that better define the diagnostic criteria of any given disease, (2) develop research models, and (3) exploit the externalities coming from innovative pharmacological protocols (i.e., those based on monoclonal antibodies, nanodrugs, etc.) meant to tackle the molecular cascade so far identified. Full article
(This article belongs to the Special Issue New Innovations in Biomedical Engineering)
►▼ Show Figures

Graphical abstract

1721 KiB  
Meeting Report
Report from the BIT’s 1st Annual World Congress of Biomedical Engineering Held in Xi’an, China, 9–11 November 2017
by Gerhard Litscher and Xiaodan Mei
Medicines 2017, 4(4), 83; https://doi.org/10.3390/medicines4040083 - 16 Nov 2017
Cited by 1 | Viewed by 7001
Abstract
We are delighted to present within this meeting report the abstracts of the “BIT’s 1st World Congress of Biomedical Engineering 2017” which has been hold in Xi’an in China [...] Full article
(This article belongs to the Special Issue New Innovations in Biomedical Engineering)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop